Abstract
A series of some newly methylsulfanyl-triazoloquinazoline derivatives (1-21) have been tested against Coxsackievirus B4 and Adenovirus type 7. The antiviral activity of the titled compounds against Coxsackie B4 and Adeno type 7 was evaluated in BGM and Hep-2 cell lines. Compounds 4, 5, and 6 represent the most populated set of compounds obtained during this study, and 4 and 6 in particular were found to display the highest activities against Coxsackie B4 and exhibited good effect against Adeno type 7. The % of reduction in the case of Coxsackie B4 titer was 63.3 % (4, 6) and 83.3 % (5), while in Adeno type 7 titer was 63.3, 50, and 66.6 % for 4, 5, and 6, respectively.